{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:20Z","timestamp":1791348740273,"version":"4.3.1"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministerio de Sanidad y Consumo","award":["CP13-00070"],"award-info":[{"award-number":["CP13-00070"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI1401648"],"award-info":[{"award-number":["PI1401648"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","award":["PI12-0291"],"award-info":[{"award-number":["PI12-0291"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.cca.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T02:39:31Z","timestamp":1454985571000},"page":"134-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics"],"prefix":"10.1016","volume":"455","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-2246","authenticated-orcid":false,"given":"Josep","family":"Julve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas M.","family":"Mart\u00edn-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Carles","family":"Escol\u00e0-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Blanco-Vaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2016.02.004_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/B978-0-12-800263-6.00003-3","article-title":"Apolipoprotein B-48: a unique marker of chylomicron metabolism","volume":"64","author":"Nakajima","year":"2014","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0010","doi-asserted-by":"crossref","first-page":"E1183","DOI":"10.1152\/ajpendo.90899.2008","article-title":"Intestinal lipid absorption","volume":"296","author":"Iqbal","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2016.02.004_bb0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-2275(20)42650-1","article-title":"Particle size and protein content of six fractions of the Sf 20 plasma lipoproteins isolated by density gradient centrifugation","volume":"10","author":"Lossow","year":"1969","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0020","first-page":"G709","article-title":"Fat feeding increases size, but not number, of chylomicrons produced by small intestine","volume":"259","author":"Hayashi","year":"1990","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cca.2016.02.004_bb0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0022-2275(20)40242-1","article-title":"The lipid composition of human plasma chylomicrons","volume":"5","author":"Wood","year":"1964","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S0007114500002853","article-title":"Fatty acid composition of an oral load affects chylomicron size in human subjects","volume":"77","author":"Sakr","year":"1997","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.cca.2016.02.004_bb0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.ejcn.1602749","article-title":"Methodology for studying postprandial lipid metabolism","volume":"61","author":"Lairon","year":"2007","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.cca.2016.02.004_bb0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-nutr-071714-034338","article-title":"New insights into the regulation of chylomicron production","volume":"35","author":"Dash","year":"2015","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.cca.2016.02.004_bb0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nutres.2014.07.005","article-title":"Test meals rich in marine long-chain n-3 polyunsaturated fatty acids increase postprandial chylomicron response","volume":"34","author":"Griffo","year":"2014","journal-title":"Nutr. Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.biopha.2014.10.008","article-title":"Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals\u2014a randomized cross-over trial","volume":"68","author":"Miyoshi","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cca.2016.02.004_bb0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2014.01.015","article-title":"Postprandial hypertriglyceridemia as a coronary risk factor","volume":"431","author":"Boren","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0060","doi-asserted-by":"crossref","first-page":"D320","DOI":"10.2741\/A613","article-title":"Signposts in the assembly of chylomicrons","volume":"6","author":"Hussain","year":"2001","journal-title":"Front. Biosci."},{"key":"10.1016\/j.cca.2016.02.004_bb0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1475-2891-12-122","article-title":"Modulation of human postprandial lipemia by changing ratios of polyunsaturated to saturated (P\/S) fatty acid content of blended dietary fats: a cross-over design with repeated measures","volume":"12","author":"Karupaiah","year":"2013","journal-title":"Nutr. J."},{"key":"10.1016\/j.cca.2016.02.004_bb0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11745-012-3735-5","article-title":"Lipidomic profiling of chylomicron triacylglycerols in response to high fat meals","volume":"48","author":"Bonham","year":"2013","journal-title":"Lipids"},{"key":"10.1016\/j.cca.2016.02.004_bb0075","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0022-2275(20)34443-6","article-title":"Plasma lipoproteins: apolipoprotein structure and function","volume":"25","author":"Mahley","year":"1984","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.ATV.7.2.166","article-title":"Mapping of human apolipoprotein B antigenic determinants","volume":"7","author":"Marcel","year":"1987","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0085","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI109074","article-title":"Intestinal apoproteins during fat absorption","volume":"61","author":"Schonfeld","year":"1978","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0090","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1152\/physrev.00019.2011","article-title":"Role of the gut in lipid homeostasis","volume":"92","author":"Abumrad","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cca.2016.02.004_bb0095","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/hmg\/dds140","article-title":"The GTPase ARFRP1 controls the lipidation of chylomicrons in the Golgi of the intestinal epithelium","volume":"21","author":"Jaschke","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cca.2016.02.004_bb0100","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0022-2275(20)31499-1","article-title":"Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein","volume":"42","author":"Blanco-Vaca","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00041433-200406000-00003","article-title":"Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility","volume":"15","author":"Martin-Campos","year":"2004","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.cca.2016.02.004_bb0110","doi-asserted-by":"crossref","first-page":"14788","DOI":"10.1073\/pnas.93.25.14788","article-title":"Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility","volume":"93","author":"Weng","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2016.02.004_bb0115","doi-asserted-by":"crossref","first-page":"11564","DOI":"10.1074\/jbc.274.17.11564","article-title":"Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis","volume":"274","author":"Boisfer","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0120","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1194\/jlr.M600112-JLR200","article-title":"Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism","volume":"47","author":"Dugue-Pujol","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0125","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/ATVBAHA.109.198226","article-title":"Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome","volume":"30","author":"Julve","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0130","doi-asserted-by":"crossref","first-page":"11633","DOI":"10.1074\/jbc.M708995200","article-title":"Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance","volume":"283","author":"Castellani","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0135","doi-asserted-by":"crossref","first-page":"10689","DOI":"10.1074\/jbc.M115.637058","article-title":"Role of conserved proline residues in human apolipoprotein A-IV structure and function","volume":"290","author":"Deng","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0140","first-page":"727","article-title":"Gut triglyceride production","volume":"2012","author":"Pan","year":"1821","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0145","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1021\/bi00361a034","article-title":"Structure, evolution, and tissue-specific synthesis of human apolipoprotein AIV","volume":"25","author":"Karathanasis","year":"1986","journal-title":"Biochemistry"},{"key":"10.1016\/j.cca.2016.02.004_bb0150","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1172\/JCI109745","article-title":"Human apolipoprotein A-IV. Intestinal origin and distribution in plasma","volume":"65","author":"Green","year":"1980","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0155","doi-asserted-by":"crossref","first-page":"G472","DOI":"10.1152\/ajpgi.00098.2014","article-title":"ApoA-IV: current and emerging roles in intestinal lipid metabolism, glucose homeostasis, and satiety","volume":"308","author":"Kohan","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cca.2016.02.004_bb0160","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1194\/jlr.R052753","article-title":"Apolipoprotein A-IV: a protein intimately involved in metabolism","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0165","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/S0021-9258(19)39557-2","article-title":"Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV","volume":"265","author":"Goldberg","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.07.019","article-title":"Apolipoprotein A-V; a potent triglyceride reducer","volume":"219","author":"Nilsson","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.atherosclerosis.2005.01.034","article-title":"Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients","volume":"181","author":"Pruneta-Deloche","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0180","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1472-6823-14-90","article-title":"Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia","volume":"14","author":"Almeda-Valdes","year":"2014","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.cca.2016.02.004_bb0185","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cca.2016.02.004_bb0190","doi-asserted-by":"crossref","first-page":"17982","DOI":"10.1074\/jbc.M212191200","article-title":"Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators","volume":"278","author":"Vu-Dac","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0195","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1074\/jbc.M607809200","article-title":"Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine","volume":"282","author":"Fu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0200","doi-asserted-by":"crossref","first-page":"G634","DOI":"10.1152\/ajpgi.00339.2014","article-title":"Apolipoprotein A-V deficiency enhances chylomicron production in lymph fistula mice","volume":"308","author":"Zhang","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cca.2016.02.004_bb0205","doi-asserted-by":"crossref","first-page":"G918","DOI":"10.1152\/ajpgi.00227.2015","article-title":"Apolipoprotein A-V is present in bile and its secretion increases with lipid absortion in Sprague\u2013Dawley rats","volume":"309","author":"Zhang","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cca.2016.02.004_bb0210","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.ATV.19.3.472","article-title":"Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3","volume":"19","author":"Jong","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0215","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0022-2275(20)41267-2","article-title":"Lipoprotein apoprotein metabolism","volume":"19","author":"Schaefer","year":"1978","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0220","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0022-2275(20)34342-X","article-title":"Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver","volume":"26","author":"Windler","year":"1985","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0225","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0230","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.metabol.2011.12.002","article-title":"A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease","volume":"61","author":"Kei","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.cca.2016.02.004_bb0235","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0006-291X(70)90468-7","article-title":"A specific apoprotein activator for lipoprotein lipase","volume":"41","author":"LaRosa","year":"1970","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2016.02.004_bb0240","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cca.2016.02.004_bb0245","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.ATV.0000201282.64751.47","article-title":"Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis","volume":"26","author":"Heeren","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0250","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/MOL.0b013e328338cabc","article-title":"Recent insights into factors affecting remnant lipoprotein uptake","volume":"21","author":"Williams","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.cca.2016.02.004_bb0255","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1172\/JCI67398","article-title":"Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans","volume":"123","author":"Gonzales","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0260","doi-asserted-by":"crossref","first-page":"32228","DOI":"10.1074\/jbc.M204053200","article-title":"Identification of the proteoglycan binding site in apolipoprotein B48","volume":"277","author":"Flood","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0265","doi-asserted-by":"crossref","first-page":"11097","DOI":"10.1016\/S0021-9258(18)60931-7","article-title":"Human apolipoprotein B-100 heparin-binding sites","volume":"262","author":"Weisgraber","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cca.2016.02.004_bb0270","doi-asserted-by":"crossref","first-page":"30979","DOI":"10.1074\/jbc.273.47.30979","article-title":"Subdomain chimeras of hepatic lipase and lipoprotein lipase. localization of heparin and cofactor binding","volume":"273","author":"Hill","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0275","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1194\/jlr.P700032-JLR200","article-title":"Chylomicron remnants are increased in the postprandial state in CD36 deficiency","volume":"50","author":"Masuda","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0280","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm.1937","article-title":"Deficiency of the intestinal enzyme acyl CoA: monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding","volume":"15","author":"Yen","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0285","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1172\/JCI64873","article-title":"DGAT1 mutation is linked to a congenital diarrheal disorder","volume":"122","author":"Haas","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0290","doi-asserted-by":"crossref","first-page":"19967","DOI":"10.1074\/jbc.M800398200","article-title":"Microsomal triglyceride transfer protein enhances cellular cholesteryl esterification by relieving product inhibition","volume":"283","author":"Iqbal","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0295","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.95.25.14733","article-title":"Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence","volume":"95","author":"Mitchell","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2016.02.004_bb0300","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0955-0674(00)00234-9","article-title":"ER export: public transportation by the COPII coach","volume":"13","author":"Antonny","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0305","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MOL.0000000000000110","article-title":"Sortilin and lipoprotein metabolism: making sense out of complexity","volume":"25","author":"Strong","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.cca.2016.02.004_bb0310","doi-asserted-by":"crossref","first-page":"25920","DOI":"10.1074\/jbc.M802721200","article-title":"Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families","volume":"283","author":"Nilsson","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0315","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1523\/JNEUROSCI.2425-12.2013","article-title":"The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-beta peptide in the brain","volume":"33","author":"Carlo","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cca.2016.02.004_bb0320","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cmet.2010.08.006","article-title":"Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export","volume":"12","author":"Kjolby","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.cca.2016.02.004_bb0325","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2014current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"issue":"Suppl. 3","key":"10.1016\/j.cca.2016.02.004_bb0330","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1002\/(SICI)1096-9136(199708)14:3+<S75::AID-DIA449>3.3.CO;2-0","article-title":"Mechanisms of hepatic chylomicron remnant clearance","volume":"14","author":"Willnow","year":"1997","journal-title":"Diabet. Med."},{"issue":"Pt 3","key":"10.1016\/j.cca.2016.02.004_bb0335","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1042\/bj2990889","article-title":"Hepatic lipase may act as a ligand in the uptake of artificial chylomicron remnant-like particles by isolated rat hepatocytes","volume":"299","author":"Diard","year":"1994","journal-title":"Biochem. J."},{"key":"10.1016\/j.cca.2016.02.004_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.12.027","article-title":"The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight","volume":"211","author":"Dallinga-Thie","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0345","first-page":"919","article-title":"Physiological regulation of lipoprotein lipase","volume":"2014","author":"Kersten","year":"1841","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0350","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1074\/jbc.M808477200","article-title":"The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms","volume":"284","author":"Shan","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0355","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5551\/jat.31617","article-title":"Hepatic lipase: a comprehensive view of its role on plasma lipid and lipoprotein metabolism","volume":"22","author":"Kobayashi","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2016.02.004_bb0360","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1194\/jlr.M900145-JLR200","article-title":"GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4","volume":"50","author":"Sonnenburg","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0365","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1152\/physrev.00033.2007","article-title":"LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies","volume":"88","author":"Lillis","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cca.2016.02.004_bb0370","first-page":"3236","article-title":"Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice","volume":"119","author":"Stanford","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0375","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1194\/jlr.M031195","article-title":"Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia","volume":"54","author":"Mendoza-Barbera","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0380","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjmed.2007.10.004","article-title":"Chylomicronemia and the chylomicronemia syndrome. A practical guide to treatment","volume":"121","author":"Leaf","year":"2008","journal-title":"Am. J. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0385","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3111\/13696998.2013.779277","article-title":"Medical resource use and cost associated with chylomicronemia","volume":"16","author":"Gaudet","year":"2013","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.cca.2016.02.004_bb0390","first-page":"117","article-title":"Pathogenesis, differentiation and management of hypertriglyceridemia","volume":"15","author":"Havel","year":"1969","journal-title":"Adv. Intern. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0395","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0400","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2016.02.004_bb0405","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2016.02.004_bb0410","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1194\/jlr.R700001-JLR200","article-title":"Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase","volume":"48","author":"Zheng","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0415","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1172\/JCI107334","article-title":"Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man","volume":"52","author":"Brunzell","year":"1973","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0420","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2012.02.001","article-title":"Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity","volume":"222","author":"Adiels","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0425","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0025-7125(16)31430-4","article-title":"Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia","volume":"66","author":"Brunzell","year":"1982","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.cca.2016.02.004_bb0430","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"1913","article-title":"Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome","author":"Brunzell","year":"1995"},{"key":"10.1016\/j.cca.2016.02.004_bb0435","doi-asserted-by":"crossref","first-page":"471","DOI":"10.7326\/0003-4819-75-3-471","article-title":"An international classification of hyperlipidemias and hyperlipoproteinemias","volume":"75","author":"Fredrickson","year":"1971","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0440","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrg2481","article-title":"Plasma lipoproteins: genetic influences and clinical implications","volume":"10","author":"Hegele","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.cca.2016.02.004_bb0445","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00231536","article-title":"Molecular genetics of human lipoprotein lipase deficiency","volume":"113","author":"Hayden","year":"1992","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.cca.2016.02.004_bb0450","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-2275(20)38019-6","article-title":"Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity","volume":"24","author":"Brunzell","year":"1983","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0455","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cca.2013.11.025","article-title":"Molecular analysis of chylomicronemia in a clinical laboratory setting: diagnosis of 13 cases of lipoprotein lipase deficiency","volume":"429","author":"Martin-Campos","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0460","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2015.04.815","article-title":"Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia","volume":"241","author":"Rabacchi","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0465","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1139\/Y09-005","article-title":"Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review","volume":"87","author":"Rahalkar","year":"2009","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.cca.2016.02.004_bb0470","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1161\/ATVBAHA.107.150680","article-title":"Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650)","volume":"27","author":"Wang","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0475","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","article-title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia","volume":"272","author":"Surendran","year":"2012","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0480","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2350-11-66","article-title":"Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study","volume":"11","author":"Ariza","year":"2010","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.cca.2016.02.004_bb0485","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-2275(20)38369-3","article-title":"Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution","volume":"30","author":"Semenkovich","year":"1989","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0490","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/CIRCGENETICS.111.960864","article-title":"Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia","volume":"5","author":"Johansen","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.cca.2016.02.004_bb0495","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1086\/513473","article-title":"Most rare missense alleles are deleterious in humans: implications for complex disease and association studies","volume":"80","author":"Kryukov","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.cca.2016.02.004_bb0500","doi-asserted-by":"crossref","first-page":"E484","DOI":"10.1210\/jc.2013-3962","article-title":"The postprandial chylomicron triacylglycerol response to dietary fat in healthy male adults is significantly explained by a combination of single nucleotide polymorphisms in genes involved in triacylglycerol metabolism","volume":"99","author":"Desmarchelier","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2016.02.004_bb0505","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2016.02.004_bb0510","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1373\/clinchem.2006.070318","article-title":"Apolipoprotein A5 S19W may play a role in dysbetalipoproteinemia in patients with the Apo E2\/E2 genotype","volume":"52","author":"Martin-Campos","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0515","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI113243","article-title":"Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E","volume":"80","author":"Weintraub","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0520","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.cca.2010.07.028","article-title":"Review on anti-lipoprotein lipase antibodies","volume":"411","author":"Rodrigues","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0525","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.atherosclerosis.2009.07.039","article-title":"Prevalence and function of anti-lipoprotein lipase auto-antibodies in type V hyperchylomicronemia","volume":"208","author":"Moret","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0530","first-page":"350","article-title":"Anti-lipoprotein lipase antibodies in patients with hypertriglyceridemia without associated autoimmune disease","volume":"13","author":"de Carvalho","year":"2011","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.cca.2016.02.004_bb0535","first-page":"791","article-title":"Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy","volume":"82","author":"Pruneta","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2016.02.004_bb0540","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ng1145","article-title":"Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders","volume":"34","author":"Jones","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cca.2016.02.004_bb0545","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.cca.2016.02.004_bb0550","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10545-013-9665-4","article-title":"Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management","volume":"37","author":"Lee","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.cca.2016.02.004_bb0555","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1210\/jc.2006-1998","article-title":"Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia","volume":"92","author":"Hooper","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2016.02.004_bb0560","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0565","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cca.2011.11.020","article-title":"Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation","volume":"413","author":"Martin-Campos","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0570","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCGENETICS.111.960674","article-title":"Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3","volume":"5","author":"Pisciotta","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.cca.2016.02.004_bb0575","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2016.02.004_bb0580","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0585","first-page":"70","article-title":"Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans","volume":"119","author":"Romeo","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0590","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1258\/acb.2010.009307","article-title":"Association of angiopoietin-like protein 3 with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma","volume":"47","author":"Nakajima","year":"2010","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.cca.2016.02.004_bb0595","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0600","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2008.08.021","article-title":"Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemic subjects","volume":"398","author":"Moon","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0605","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","article-title":"Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids","volume":"33","author":"Robciuc","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0610","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10654-010-9501-1","article-title":"Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study","volume":"25","author":"Lindman","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.cca.2016.02.004_bb0615","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.ATV.0000173310.85845.7b","article-title":"Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study","volume":"25","author":"Imke","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0620","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2016.02.004_bb0625","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.90.5.2069","article-title":"Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans","volume":"90","author":"Schneeman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2016.02.004_bb0630","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/S0022-2275(20)35345-1","article-title":"Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters","volume":"34","author":"Cohn","year":"1993","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0635","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/01.ATV.15.2.199","article-title":"Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100","volume":"15","author":"Karpe","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0640","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/01.ATV.0000084638.14534.0A","article-title":"Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits","volume":"23","author":"Proctor","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0645","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-2362.2012.02687.x","article-title":"Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence","volume":"42","author":"Masuda","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.cca.2016.02.004_bb0650","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2013.02.005","article-title":"Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease","volume":"421","author":"Mori","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0655","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2011.05.009","article-title":"Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels","volume":"218","author":"Nakatani","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0660","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1194\/jlr.M600548-JLR200","article-title":"Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes","volume":"48","author":"Hogue","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0665","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1464-5491.2010.03138.x","article-title":"Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans","volume":"28","author":"Mangat","year":"2011","journal-title":"Diabet. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0670","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cca.2009.12.022","article-title":"Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls","volume":"411","author":"Valdivielso","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0675","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.atherosclerosis.2012.05.038","article-title":"Fasting apolipoprotein B48 is associated with asymptomatic peripheral arterial disease in type 2 diabetic subjects: a case\u2013control study","volume":"223","author":"Lapice","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0680","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0021-9150(99)00364-0","article-title":"Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease","volume":"150","author":"Mero","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0685","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0021-9150(99)00275-0","article-title":"Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes","volume":"148","author":"Phillips","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0690","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/01.ATV.14.4.622","article-title":"Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins","volume":"14","author":"Chung","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.cca.2016.02.004_bb0695","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1515\/CCLM.2003.120","article-title":"Identification of lipoproteins of intestinal origin in human atherosclerotic plaque","volume":"41","author":"Pal","year":"2003","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0700","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cca.2007.12.012","article-title":"Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases","volume":"390","author":"Nakano","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0705","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/0005-2760(81)90277-0","article-title":"Uptake of chylomicron remnants by the native LDL receptor in human monocyte-derived macrophages","volume":"665","author":"Floren","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0710","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/cs1010111","article-title":"Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins","volume":"101","author":"Elsegood","year":"2001","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.cca.2016.02.004_bb0715","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2005.10.043","article-title":"An investigation by electron microscopy of chylomicron remnant uptake by human monocyte-derived macrophages","volume":"188","author":"Elsegood","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0720","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.plipres.2013.06.001","article-title":"Postprandial lipoproteins and the molecular regulation of vascular homeostasis","volume":"52","author":"Botham","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0725","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2003.08.016","article-title":"Chylomicron remnants induce monocyte chemoattractant protein-1 expression via p38 MAPK activation in vascular smooth muscle cells","volume":"171","author":"Domoto","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0730","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.lfs.2005.01.012","article-title":"Chylomicron remnants regulate early growth response factor-1 in vascular smooth muscle cells","volume":"77","author":"Takahashi","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.cca.2016.02.004_bb0735","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/01.ATV.0000222015.76038.14","article-title":"Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans","volume":"26","author":"Duez","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0740","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00125-006-0177-8","article-title":"Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann\u2013Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein","volume":"49","author":"Lally","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.cca.2016.02.004_bb0745","first-page":"142","article-title":"Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes","volume":"2011","author":"Bozzetto","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0750","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jnutbio.2014.01.004","article-title":"Sar1b transgenic male mice are more susceptible to high-fat diet-induced obesity, insulin insensitivity and intestinal chylomicron overproduction","volume":"25","author":"Levy","year":"2014","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.cca.2016.02.004_bb0755","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0b013e32834d68f0","article-title":"Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states","volume":"23","author":"Farr","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.cca.2016.02.004_bb0760","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00125-005-0126-y","article-title":"Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans","volume":"49","author":"Meier","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.cca.2016.02.004_bb0765","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsb\u00f8ll","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.cca.2016.02.004_bb0770","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0775","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2010.05.028","article-title":"Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus","volume":"212","author":"Schwartz","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0780","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI200419992","article-title":"Foxo1 mediates insulin action on apoC-III and triglyceride metabolism","volume":"114","author":"Altomonte","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.02.004_bb0785","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/ATVBAHA.114.304873","article-title":"Central Nervous system regulation of intestinal lipoprotein metabolism by glucagon-like peptide-1 via a brain-gut axis","volume":"35","author":"Farr","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.02.004_bb0790","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.cca.2011.04.018","article-title":"Postprendial lipoprotein metabolism: VLDL vs chylomicrons","volume":"412","author":"Nakajima","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0795","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0009-8981(93)90062-9","article-title":"Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels","volume":"223","author":"Nakajima","year":"1993","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0800","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1373\/clinchem.2007.092296","article-title":"Development of a homogeneous assay to measure remnant lipoprotein cholesterol","volume":"53","author":"Miyauchi","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2016.02.004_bb0805","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2011.04.040","article-title":"Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals","volume":"218","author":"Nakamura","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.02.004_bb0810","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-2275(20)37199-6","article-title":"A single copy of apolipoprotein B-48 is present on the human chylomicron remnant","volume":"38","author":"Phillips","year":"1997","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.02.004_bb0815","article-title":"Familial Lipoprotein Lipase","author":"Brunzell","year":"1999"},{"key":"10.1016\/j.cca.2016.02.004_bb0820","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbalip.2011.10.011","article-title":"Fish-oil\u2014how does it reduce plasma triglicerides?","volume":"182","author":"Shearer","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cca.2016.02.004_bb0825","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2013.169","article-title":"Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy","volume":"25","author":"Ferreira","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.cca.2016.02.004_bb0830","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-014-0339-9","article-title":"Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.cca.2016.02.004_bb0835","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemic syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2016.02.004_bb0840","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989811630047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989811630047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T17:46:45Z","timestamp":1654278405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000989811630047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":168,"alternative-id":["S000989811630047X"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2016.02.004","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2016.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}